Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 March 2025
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 4 June 2025
Suspected sepsis: recognition, diagnosis and early managementStatus:In developmentProgramme:NICE guidelineExpected publication date: 13 August 2025
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 August 2025
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 December 2025
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC